X4 PHARMACEUTICALS, INC.
61 North Beacon Street, 4th Floor
Boston, MA 02134
May 12, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
| RE: | X4 Pharmaceuticals, Inc. |
Registration Statement on Form S-3
File No. 333-264459
Acceleration Request
Requested Date: May 13, 2022
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-264459) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, May 13, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
| Sincerely, | ||
| X4 Pharmaceuticals, Inc. | ||
| By: | /s/ Adam S. Mostafa | |
| Adam S. Mostafa | ||
| Chief Financial Officer | ||
| cc: | Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc. |
Derek Meisner, Chief Legal Officer, X4 Pharmaceuticals, Inc.
Daniel I. Goldberg, Cooley LLP
Courtney T. Thorne, Cooley LLP